ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed the supplemental Biologics License Application (sBLA) supporting the conversion of the accelerated approval of ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens to full approval. The application has been granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) action date of April 5, 2024.
Evolv Technology Responds To Short Seller Misinformation; Says Evolv Is Committed To Our Mission Of Making The World Safer And Stands Behind Our Technology As Vetted By Hundreds Of Security Professionals In Real World Environments
Evolv Technology was founded in 2013 as a next-generation physical security company committed to making the world a safer place. Over a decade later, and with the trust of former leaders of the Central Intelligence
